Elevated Total Lymphocyte Count in CKD Patient on Hydroxychloroquine
A total lymphocyte count (TLC) of 29,000/µL (29 × 10³/µL) is markedly elevated and requires immediate investigation for underlying causes including infection, hematologic malignancy, or medication effects, while simultaneously addressing hydroxychloroquine dosing in the context of chronic kidney disease.
Significance of TLC 29,000/µL
This represents lymphocytosis (normal range typically 1,000-4,000/µL). The elevation is substantial and warrants urgent evaluation:
Primary Concerns to Investigate:
- Hematologic malignancy: Chronic lymphocytic leukemia (CLL), lymphoma, or acute lymphoblastic leukemia
- Infectious causes: Viral infections (EBV, CMV, pertussis), though less likely with this degree of elevation
- Medication effects: While hydroxychloroquine typically causes lymphopenia rather than lymphocytosis 1, 2
- Autoimmune disease activity: Given the patient is on hydroxychloroquine, underlying lupus or connective tissue disease flare
Critical Hydroxychloroquine Dosing Issue
The patient's hydroxychloroquine dose must be urgently reassessed given the creatinine of 2.2 mg/dL, as this represents significant renal impairment:
Renal Impairment and HCQ Toxicity:
- Hydroxychloroquine is substantially excreted by the kidney, and renal disease effectively increases circulating drug levels and toxicity risk 3
- Dose reduction is necessary in patients with renal disease 1
- Patients with renal disease can have unpredictably high blood drug levels 3
- The FDA label explicitly states: "A reduction in the dosage of hydroxychloroquine sulfate may be necessary in patients with hepatic or renal disease" 1
Recommended Dosing Adjustment:
- Standard dosing should not exceed 5.0 mg/kg based on actual body weight 4, 3
- With CKD (creatinine 2.2), reduce dose by 50% or more depending on estimated GFR
- Consider holding temporarily if GFR <30 mL/min until toxicity assessment complete
Immediate Management Steps
1. Urgent Laboratory Workup:
- Complete blood count with differential (confirm absolute lymphocyte count, evaluate for blasts)
- Peripheral blood smear review
- Flow cytometry if lymphocyte morphology abnormal
- Lactate dehydrogenase (LDH), uric acid
- Calculate estimated GFR to guide HCQ dosing
2. Assess for HCQ Toxicity 1:
- Hematologic toxicity: HCQ can cause myelosuppression including leukopenia, though lymphocytosis is paradoxical
- Monitor for other toxicities:
- Cardiac: QTc prolongation, arrhythmias
- Ophthalmologic: Retinal toxicity (though typically with chronic use)
- Hepatic: Transaminases
- Metabolic: Hypoglycemia, hypokalemia 5
3. Hydroxychloroquine Management:
- Temporarily hold HCQ until lymphocytosis etiology clarified and renal function reassessed
- When restarting, use reduced dose appropriate for renal function
- Monitor blood cell counts periodically on long-term therapy 1
4. Rule Out Malignancy:
- If lymphocytosis persists or worsens, or if atypical cells present: urgent hematology consultation
- Consider bone marrow biopsy if flow cytometry suggests clonal process
5. Monitor Renal Function 1:
- HCQ can cause proteinuria and reduced GFR through phospholipidosis 1
- Check urinalysis for proteinuria
- Serial creatinine monitoring
Key Clinical Pitfalls
Do not assume the lymphocytosis is benign or reactive without proper workup - this degree of elevation demands exclusion of hematologic malignancy.
Do not continue full-dose hydroxychloroquine in a patient with creatinine 2.2 mg/dL - this significantly increases toxicity risk across multiple organ systems 3, 1.
Do not attribute lymphocytosis to hydroxychloroquine - HCQ typically causes lymphopenia, not lymphocytosis 2. Research shows HCQ reduces lymphocyte counts in CKD patients 6, 7.
The paradoxical finding of lymphocytosis in a patient on HCQ with CKD suggests either: (1) an independent hematologic process requiring urgent evaluation, or (2) severe underlying autoimmune disease activity overwhelming the immunosuppressive effects of HCQ.